Canada · Delayed Price · Currency is CAD Sernova Biotherapeutics Statistics
Total Valuation
TSX:SVA has a market cap or net worth of CAD 65.18 million. The enterprise value is 69.78 million.
| Market Cap | 65.18M |
| Enterprise Value | 69.78M |
Important Dates
The next estimated earnings date is Tuesday, December 23, 2025.
| Earnings Date | Dec 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSX:SVA has 395.04 million shares outstanding. The number of shares has increased by 7.27% in one year.
| Current Share Class | 395.04M |
| Shares Outstanding | 395.04M |
| Shares Change (YoY) | +7.27% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.48% |
| Owned by Institutions (%) | n/a |
| Float | 381.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -2.67 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.77 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.02
| Current Ratio | 0.02 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -258.62% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 73.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.42M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TSX:SVA has paid 71,402 in taxes.
| Income Tax | 71,402 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.29% in the last 52 weeks. The beta is 0.80, so TSX:SVA's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -35.29% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.19 |
| Relative Strength Index (RSI) | 38.36 |
| Average Volume (20 Days) | 105,318 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.31M |
| Pretax Income | -18.44M |
| Net Income | -18.51M |
| EBITDA | -17.07M |
| EBIT | -17.31M |
| Earnings Per Share (EPS) | -0.06 |
Balance Sheet
The company has 83,617 in cash and 4.69 million in debt, giving a net cash position of -4.60 million or -0.01 per share.
| Cash & Cash Equivalents | 83,617 |
| Total Debt | 4.69M |
| Net Cash | -4.60M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -24.43M |
| Book Value Per Share | -0.07 |
| Working Capital | -23.87M |
Cash Flow
| Operating Cash Flow | -14.66M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSX:SVA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.27% |
| Shareholder Yield | -7.27% |
| Earnings Yield | -28.40% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |